SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- 3 gastroenterology physicians face lawsuits in 1 week (Becker’s GI & Endoscopy)
- Centralized Colorectal Cancer Screening Outreach in Federally Qualified Health Centers (JAMA Network)
- Gut Check: New Study Challenges Gastroparesis Diagnostics (GI & Endoscopy News)
- Capitalizing On The GI M&A Market, With Sap Sinha (Podcast) (The Corner Series)
- As GLP-1 Use Surges, Clinicians Weigh Benefits and Risks (Medscape)
- New HHS leader could overhaul Medicare physician reimbursement: reports (Medical Economics)
- UnitedHealth pays its own physician groups considerably more than others, driving up consumer costs and its profits (STAT)
- Innovating Personalized Care: The Future of Gastroenterology (ASGE)